Please fill out the form below and we will gladly respond as soon as possible.
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option. A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed […]
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For years, research and therapeutic development have focused on how this fusion interacts with the SWI/SNF chromatin remodeling complex, believed to play a central role in tumor growth. However, newly published research challenges that long-standing assumption […]
Join the Synovial Sarcoma Foundation for a live, one-hour webinar focused on where synovial sarcoma research is heading and what that progress means for patients and families today. The conversation will bring together real patient experiences with insights from researchers and clinicians leading efforts in synovial sarcoma. We’ll discuss emerging research, areas of real momentum, […]
Synovial sarcoma most often develops near the large joints of the arms or legs, but in rare cases it can arise in the head and neck region. An especially uncommon presentation occurs in infants. A recently published case report describes synovial sarcoma originating in the parotid gland—the salivary gland located near the jaw and ear—in […]
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for ZI-MA4-1 (ZIMA-101), a first-in-human cell therapy study that will include patients with synovial sarcoma. While this trial is still in its earliest phase, it represents a notable scientific development for the synovial sarcoma community. What […]
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the state to receive a cutting-edge immune-cell therapy, TECELRA, at the HonorHealth Research Institute in Scottsdale. Synovial sarcoma is a rare soft-tissue cancer that primarily affects large joints in the arms and legs, though it can […]
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive fibroblast that still carries embryonic markers (Hic1⁺ Pdgfra⁺ Lgr5⁺). Breaking 2025 Research: Read the entire article here. Learn more about our world-renowned registry efforts here.
Not every detected cancer is clinically meaningful. For younger patients, especially, this can mean confronting a diagnosis that may never progress but still carries psychological and treatment burdens.